Jaguar Health Announces All Pediatric Participants In Napo Pharmaceuticals' Crosover Clinical Study Have Entered Extension Phase To Get Doses Of Crofelemer To Treat Microvillus Inclusion Disease

Loading news article.

Jaguar Health Announces All Pediatric Participants In Napo Pharmaceuticals' Crosover Clinical Study Have Entered Extension Phase To Get Doses Of Crofelemer To Treat Microvillus Inclusion Disease | WAPE

Jaguar Health Announces All Pediatric Participants In Napo Pharmaceuticals' Crosover Clinical Study Have Entered Extension Phase To Get Doses Of Crofelemer To Treat Microvillus Inclusion Disease

Article summary

Related companies

Analyzed by WAPE AI.

Comments —